In vitro, bevacizumab exhibits pro-apoptotic effects on CLL cells [182]: it triggers leukemia cell death, with activation of caspases 3/9, overexpression of the proapoptotic factors Bak and Bad, and downregulation of Mcl-2 and AKT [182] (Table 2). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.